ClinicalTrials.gg
CompletedNCT06118021Updated Jun 4, 2026

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

A Phase 2 interventional study of HS-20094 and Placebo in Overweight and Obesity, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
171st of 502
200 · median 120
Started
2023
with 49 others
Phase 2
52 of 600
17 open now
Registered
231st of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 171st largest by enrollment of the 502 interventional ones that give a count, is one of 50 that started in 2023, is one of 52 in phase 2, and was the 231st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight. The study period including 4-12 weeks dose titration and 12-20 weeks maintain treatment and 6 weeks follow up.

Read the detailed description

This is a phase 2, double-blind, randomised, placebo-controlled trial to assess the efficacy of HS-20094 in Chinese subjects with overweight or obesity. We enrolled adults (aged 18-65 years, both inclusive) with overweight (body-mass index [BMI] ≥24 kg/m2) accompanied by at least one obesity-related comorbidity or obesity (BMI ≥28 kg/m2) from over 10 hospitals in China. Eligible participants were randomly assigned (4:1) within each cohort by using an interactive web-response system to receive once-weekly subcutaneous HS-20094 or placebo for 24 weeks in one of the 4 cohorts below:the 5 mg cohort (5 mg weeks 1-24) ,the 10 mg cohort(5 mg weeks 1-4,10 mg weeks 5-24),the 15 mg cohort(5 mg weeks 1-4,10 mg weeks 5-8,15 mg weeks 9-24),the 20 mg cohort(5 mg weeks 1-4,10 mg weeks 5-8,15 mg weeks 9-12,20 mg weeks 13-24). The participants, investigators, study site personnel involved in treating and assessing participants in each cohort and sponsor personnel were masked to treatment allocation. The primary endpoints were the percent change in bodyweight from baseline and bodyweight reduction of 5% or higher. The secondary outcomes included the change from baseline to week 24 in waist circumference and BMI.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 200 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects,18-65 years of age at the time of signing .
  2. ≥28.0kg/m2 or 24≤BMI\<28.0 kg/ m2 with at least 1 weight-related comorbidity at screening visit.
  3. Diet and exercise control for at least 3 months before screening visit,and less than 5 kg self-reported change within the last 3 months.

Exclusion criteria

Exclusion Criteria:

  • 1. Presence of- lab or results that may affect the evaluation of the efficacy or safety of the study drug at screening visit.

    2. poor-controlled hypertension. 3. PHQ-9 score≥15. 4. Medical history or illness that affects your weight. 5. Use of any medication or treatment that may have caused significant weight change within 3 months.

    6. History of bariatric surgery. 7. History of diabetes. 8. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening.

    9. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening.

    10. Any organ-system developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix.

    11. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness.

    12. History of alcohol and/or substance abuse or drug abuse within 1 year prior to screening.

    13. Participation in other clinical trials for any weight-loss indication within 3 months prior to screening, or participation in other clinical trials for any drug or medical device within 1 month prior to screening.

    14. Known or suspected to trial product(s)or related products. 15. Female who is pregnant,breast-feeding or intends to become pregnant or is of and not using an adequate method.

    16. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme,and their immediate family members.

    17. In the judgment of the investigator,there are circumstances that affect the safety of the subject or any other interference with the evaluation of the test results.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    HS-20094 5mg

    Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.

    Drug: HS-20094 · Drug: Placebo

  • Experimental
    HS-20094 10mg

    Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.

    Drug: HS-20094 · Drug: Placebo

  • Experimental
    HS-20094 15mg

    Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.

    Drug: HS-20094 · Drug: Placebo

  • Experimental
    HS-20094 20mg

    Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.

    Drug: HS-20094 · Drug: Placebo

Interventions

  • Administered SC

    Also known as: HS-20094 injection

  • DrugPlacebo

    Administered SC

    Also known as: Placebo injection

07

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Percent Change from Baseline in Body Weight

    Time frame: From Week 0 to Week 24

Secondary outcomes

  1. Number of AEs During the Trial

    Safety

    Time frame: From Week 0 to Week 24

  2. Change from Baseline in Patient Health Questionnaire-9 (PHQ-9)

    Time frame: From Week 0 to Week 24

  3. Change from Baseline in Columbia Suicide Severity Rating scale ( C-SSRS)

    Time frame: From Week 0 to Week 24

  4. 12-lead electrocardiogram (ECG) parameters: PR, R-R, QRS and QTcF (average)

    Time frame: From Week 0 to Week 24

  5. Change from baseline in waist circumference after 24 weeks of treatment

    Time frame: From Week 0 to Week 24

  6. Change from baseline in BMI after 24 weeks of treatment

    Time frame: From Week 0 to Week 24

  7. Change from baseline in blood pressure after 24 weeks of treatment

    Time frame: From Week 0 to Week 24

  8. Change from baseline in total cholesterol after 24 weeks of treatment

    Time frame: From Week 0 to Week 24

  9. Change from baseline in fasting plasma glucose(FPG)after 24 weeks of treatment

    Time frame: From Week 0 to Week 24

08

Study locations

2 sites
  • the Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 100044, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Aug 2024, 9 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Nov 7, 2023
StartActual
Oct 16, 2023
Primary completionActual
Aug 13, 2024
CompletionActual
Aug 13, 2024
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118021
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Oct 16, 2023
Primary completion
Aug 13, 2024
Completion
Aug 13, 2024
Last update
Jun 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20094

Start the discussion